Forms of Collaboration
- Health at Bayer
Treatments & Therapies
- Chronic Kidney Disease
- Eye Conditions
- Healthy Aging
- Hormonal & Reproductive Health
Innovation & Technologies
- News & Stories
- Clinical Trials Explorer
- Treatments & Therapies
- Our Commitments
Strong partnerships have the power to spark innovation that one organization could not create on its own: Complementing our comprehensive in-house expertise with the know-how of excellent partners from academia and industry is therefore integral to our innovation strategy at Bayer.
With our global organization
and Regional Partnering Teams, we work together in all phases of the value chain with academia and industry – from research to development and production to marketing.
The best collaborative solution for your project
Sustainable alliances need a solid basis. We welcome many different forms of cooperation along the value-chain, from traditional licensing agreements or strategic alliances to public-private partnerships or open innovation models. Together with you, we will find the right set-up to meet the needs of both sides and tap the full potential of your project.
From comprehensive to focused licensing agreements
The broad spectrum of our licensing agreements can range from very comprehensive approaches and multiple assets to focused single asset options in early or later stages of the drug development process. We acquire licenses of novel small-molecule and biologic candidates, from pre-clinical leads to clinical development candidates and marketed products. Early-stage projects will then be jointly developed together with our partner, before we can further advance the project up to registration and launch in the market. In addition, we in-license early-stage discovery technologies and enabling platform technologies to support our internal small molecule and biologics drug discovery.
An Example of a multiple asset licensing agreement on early-stage projects is our strategic alliance with Compugen Ltd. in the area of cancer immunotherapy. Our collaboration with Merck & Co. in the field of soluble guanylate cyclase (SGC) modulation is an example for such cooperation in the later stages of drug development and commercialization.
An example of a very focused single asset licensing agreement is the collaboration with Orion Corporation on the co-development and commercialization of a novel oral androgen receptor inhibitor for the treatment of patients with prostate cancer, which is currently being tested in a Phase III clinical trial.
We also welcome research alliances under very comprehensive licensing agreements with academic institutes and research centers, whose technologies complement our own expertise in our core research areas.
Examples for such alliances in the academic field include collaborations with the German Cancer Research Center (DKFZ) in Heidelberg, Germany, Tsinghua University in Beijing, China, or the Broad Institute in Cambridge, USA.
Science and technology progress at lightning speed, creating new worlds of opportunities. We embrace new approaches of crowdsourcing and open innovation with partners from academic and start-up environments to leverage the fast-increasing knowledge – for example through our Grants4Targets, Grants4Leads, Grants4Apps and PartnerYourAntibodies initiatives. Those are web-based crowd-sourcing initiatives offering grants for scientists from universities, academic research institutes, and startup companies or health-IT developers to support specific projects.
The Bayer CoLaborator, our research incubator, offers young life-sciences companies the opportunity to set up their research laboratories on our campuses in Mission Bay, USA, and Berlin, Germany. The incubator concept offers young companies access to our research expertise and infrastructure and a first point of contact in the search for partnering options in the pharmaceutical industry. Thus, the CoLaborator creates an ideal environment to advance research and innovation in the life sciences.
In pre-competitive collaboration models, we join forces with partners from academia and the industry but also patient organizations and regulatory authorities to advance fundamental research and develop platform technologies to broaden the foundation for future research and fuel the momentum of medical innovation. For instance, we actively contribute to the Innovative Medicines Initiative (IMI and IMI2) and the Structural Genomics Consortium (SGC).